CurrentColorado Rocky Mountain Health PlansPolicy 2026T0322LL

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Commercial and Individual Exchange Medical Policyopen_in_new

Defines medical necessity and investigational/unproven determinations for minimally invasive procedures for GERD, gastroparesis, achalasia, and diffuse esophageal spasm for UnitedHealthcare Commercial and Individual Exchange plans. Includes coverage rationale, definitions, description of services, evidence summaries, and applicable CPT codes.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Commercial and Individual Exchange Medical Policyopen_in_new

Policy CodePolicy 2026T0322LL

Change TypeMixed (additions, removals, revisions)

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain prior authorization as applicable and document diagnoses, prior therapies, objective testing, and informed consent to confirm member eligibility and medical necessity before performing GES, pyloroplasty, POEM, or related procedures.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' to current title.

Gastric electrical stimulation (GES) therapy is designated proven and medically necessary for refractory gastroparesis and chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis.

Surgical pyloroplasty (open or laparoscopic) is designated proven and medically necessary for refractory gastroparesis and chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis.

Language stating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia was removed.

Applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to the policy.

Supporting Information sections (Description of Services, Clinical Evidence, FDA, References) were updated.

Definition of 'Gastroparesis' was updated.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3Proven/medically necessary procedures

4Unproven/not medically necessary

16CPT codes listed

70%G-POEM 1yr success (approx.)

87%POEM pooled success (SEDs)

insufficientDurability/safety certainty

Coverage Summary

This policy defines medical necessity and investigational/unproven determinations for minimally invasive and surgical procedures for GERD, gastroparesis, achalasia, and spastic esophageal disorders for UnitedHealthcare Commercial and Individual Exchange plans. Coverage positions are mixed: some procedures are designated proven/medically necessary (e.g., GES for refractory gastroparesis, surgical pyloroplasty, POEM for achalasia/diffuse esophageal spasm) while others are designated unproven/not medically necessary (e.g., G-POEM for gastroparesis; various endoscopic/implantable GERD therapies) as summarized in the policy coverage rationale. The policy is effective February 1, 2026 and applies to UnitedHealthcare Commercial and Individual Exchange members; member-specific benefit plan documents and applicable laws govern final coverage determinations.

Quick thresholds and counts

Hiatal hernia size inclusion criterion<= 2 cm reported for GERDx inclusion; < 3 cm used in LINX trial; some EsophyX studies included 2–5 cm

PPI treatment duration for study inclusion> 6 months or daily PPI use required in GERDx and many TIF/EsophyX studies

Procedures designated proven/medically necessary (count)3 procedures designated proven: GES, surgical pyloroplasty, POEM for achalasia/DES

Procedures designated unproven/not medically necessary (count)4 procedures/uses listed as unproven: POEM other indications, G-POEM, GERD endoscopic/injection/LINX/GERDx (policy groups these as investigational/unproven)

Medical-Necessity Criteria

Coverage Rationale - Gastric Electrical Stimulation (GES)

Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory Gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to Gastroparesis of diabetic or idiopathic etiology. Refer to the U.S. Food and Drug Administration (FDA) section for information regarding FDA labeling and Humanitarian Device Exemption (HDE) for GES.

GES is considered medically necessary when used to treat refractory gastroparesis (diabetic or idiopathic) after failure of medical therapy and supportive measures.

Documentation of objective delayed gastric emptying (e.g., scintigraphy) and failure of appropriate pharmacologic and dietary therapies is required for coverage.

Refer to the FDA section for device-specific labeling and HDE status; FDA HDE approval does not alter the medical necessity determination when clinical criteria are met.

Coverage Rationale - Surgical Pyloroplasty

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory Gastroparesis that has failed other therapies, or chronic-intractable (drug-refractory) nausea and vomiting secondary to Gastroparesis of diabetic or idiopathic etiology.

Not Medically Necessary / Investigational

Consolidated Noncoverage Determinations

Consolidated explicit noncoverage determinations from the policy:

POEM when performed for indications other than Achalasia or Diffuse Esophageal Spasm (e.g., Zenker's diverticulum) is unproven and considered not medically necessary due to insufficient evidence of efficacy.

G-POEM is unproven and not medically necessary for the treatment of Gastroparesis outside of clinical trials or established indications due to insufficient quality evidence on long-term safety and durability.

Endoscopic and injectable/implantable therapies for GERD (including endoscopic plication/suturing, Stretta radiofrequency, injectable bulking agents such as Plexiglas/Durasphere, and investigational endoluminal devices like GERDx™) are considered unproven and not medically necessary due to insufficient and low-quality evidence of efficacy and durability.

LINX Reflux Management System (magnetic sphincter augmentation) is considered unproven/not sufficiently established for long-term safety and durability in some evidence assessments and therefore may be considered not medically necessary in contexts where the policy lists it as unproven; long-term risks include dysphagia and device removal/erosion.

Applicable Codes

Referenced Procedure CPT Codes (for reference only)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

Added/Updated CPT Codes (Applicable Codes)CPT

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

FDA PMA/510(k) devices discussed (informational)mixed

P100049	LINX Reflux Management System PMA number (Torax Medical) - informational reference
K233240	GERDx-System 510(k) Number K233240 (Premarket Notification) - informational reference
K143634	MUSE System 510(k) approval K143634 - informational reference
K071651	Bard EndoCinch 510(k) / PMN reference K071651 - informational reference
K071553	NDO Surgical Endoscopic Plication System PMN K071553 - informational reference
k103017	Stretta System PMN k103017 - informational reference
P980053	Durasphere PMA number P980053 - informational reference
376493	Enterra Therapy System HDE id 376493 - informational reference

Provider Actions & Operational Requirements

Prior Authorization

Prior authorization likely required for procedures

Prior authorization is likely required for many novel endoscopic and minimally invasive upper GI procedures. Prior authorization may be requested to determine medical necessity and member benefit eligibility. Providers should obtain prior authorization when indicated to reduce risk of claim denials.

Prior authorization recommended for novel endoscopic procedures (e.g., POEM, G-POEM, Z-POEM, endoscopic plication, GERDx™, MUSE™).
Prior authorization may be required based on the member's specific benefit plan; verify member-specific coverage before scheduling.
Prior authorization requests should include complete clinical documentation and prior therapies tried.

Documentation Required

Medical records required for review

Medical records and supporting documentation may be requested for coverage assessment. Submission of records is necessary to evaluate whether the clinical criteria are met but does not guarantee coverage.

Background and Evidence Summary

This policy addresses diseases and procedures for upper GI disorders including GERD, gastroparesis, achalasia, and spastic esophageal disorders. Gastroparesis is characterized by delayed gastric emptying with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain, and requires objective evidence of delayed gastric emptying in symptomatic patients; scintigraphy is the reference standard for measuring gastric emptying. Gastric electrical stimulation (GES) implants electrical stimulators to the stomach to enhance motility; pyloroplasty enlarges the pyloric outlet (open or laparoscopic) to improve gastric outflow; per-oral endoscopic myotomy (POEM) involves submucosal tunneling and cutting of esophageal muscle fibers for achalasia and spastic disorders. The Enterra GES system carries an FDA Humanitarian Device Exemption indication for chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis (informational).

Evidence summary and conclusions

Summarized evidence conclusions and trial findings:

POEM: Multiple studies and randomized trials demonstrate POEM is effective and safe for achalasia with durable symptom improvement in many series; POEM shows noninferiority to laparoscopic Heller myotomy in randomized trials but may have higher reflux rates.

Z-POEM: Limited observational and comparative studies suggest short-term symptom resolution comparable to flexible endoscopic septotomy, but long-term comparative effectiveness and safety data are limited and of low quality.

Definitions

Definitions: Achalasia — a primary esophageal motor disorder with impaired EGJ relaxation and loss of organized peristalsis. Diffuse Esophageal Spasm — a rare motility disorder with simultaneous, uncoordinated contractions and dysphagia. Gastroesophageal Reflux Disease (GERD) — disorder due to LES dysfunction permitting reflux of stomach contents into the esophagus. Gastroparesis — delayed gastric emptying in symptomatic patients (definition updated in the policy) with scintigraphy as the reference standard. POEM — per-oral endoscopic myotomy for achalasia and spastic esophageal disorders. Z-POEM — Zenker's peroral endoscopic myotomy for Zenker's diverticulum. G-POEM — gastric per-oral endoscopic myotomy for refractory gastroparesis. Stretta — endoscopic radiofrequency energy delivery system for GERD. EFTP — endoscopic full-thickness fundoplication (endoscopic plication/suturing). TIF — transoral incisionless fundoplication (EsophyX/MUSE). MSA (LINX) — magnetic sphincter augmentation (laparoscopic magnetic ring around the LES). GES (Enterra) — gastric electrical stimulation device approved under HDE for chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis.

Revision History

02/01/2026revised

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' to current title.

02/01/2026added

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Commercial and Individual Exchange Medical Policyopen_in_new

Policy CodePolicy 2026T0322LL

Change TypeMixed (additions, removals, revisions)

Effective DateFeb 1, 2026

Next Review Date

SourceLink

On This Page

Pyloroplasty (open or laparoscopic) is covered when performed to relieve gastric outlet obstruction or to improve gastric emptying in patients with refractory gastroparesis after failure of conservative and pharmacologic therapies.

Clinical documentation should demonstrate objective delayed gastric emptying and prior trial of less invasive therapies.

Coverage Rationale - Per Oral Endoscopic Myotomy (POEM)

The per oral endoscopic myotomy (POEM) procedure is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm. Per oral endoscopic myotomy (POEM) is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

ANY of the following

POEM is medically necessary for adults with Achalasia when performed by providers with demonstrated expertise in advanced endoscopic and myotomy techniques and when conventional therapies are inappropriate or have failed.
POEM is medically necessary for patients with distal (classic) Achalasia subtypes and may be considered for other subtypes based on specialist evaluation and manometric findings.
POEM is medically necessary for select patients with Diffuse Esophageal Spasm when symptoms are severe, refractory to medical therapy, and objective testing supports the diagnosis.

Not medically necessary for

POEM is considered unproven and not medically necessary for indications other than Achalasia or Diffuse Esophageal Spasm, including but not limited to Zenker's diverticula, due to insufficient evidence of efficacy and safety.

Coverage Rationale - Gastric POEM (G-POEM)

Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of Gastroparesis.

G-POEM is considered investigational, unproven, and not medically necessary for treating gastroparesis due to insufficient evidence of sustained clinical benefit and long-term safety.

Coverage Rationale - GERD Endoscopic/Implantable Therapies

The following endoscopic/implantable therapies are unproven and not medically necessary for treating Gastroesophageal Reflux Disease (GERD) due to insufficient evidence of efficacy:

Endoscopic therapies (general)

Injection or implantation techniques

LINX Reflux Management System

Endoluminal therapy with GERDx™ (G-SURG) — investigational, unproven, and not medically necessary as it has not received FDA approval

Evidence-based conclusions and applicability

Evidence-based conclusions and applicability:

GES: Evidence supports use in refractory diabetic or idiopathic gastroparesis with drug-refractory nausea and vomiting; applicability limited to patients who have objective delayed gastric emptying and have failed medical therapy.

Pyloroplasty: Surgical pyloroplasty (open or laparoscopic) is applicable for refractory gastroparesis causing gastric outlet obstruction or delayed emptying after conservative measures have failed.

POEM: Strong evidence supports POEM for Achalasia and selected diffuse esophageal spasm patients; POEM is not supported for other indications.

G-POEM: Current evidence is insufficient to demonstrate long-term benefit; therefore G-POEM remains investigational and not medically necessary for gastroparesis.

GERD endoscopic/implantable therapies: Multiple endoscopic and implantable approaches lack sufficient high-quality evidence and/or FDA approval (e.g., GERDx™) and are considered investigational and not medically necessary.

Summary of material changes: Added/clarified coverage statements concerning GES, surgical pyloroplasty, POEM, G-POEM, and GERD endoscopic/implantable therapies; emphasized requirement for objective diagnostic testing and prior therapy failure where applicable.

Removed / Revised Coverage Statements: Previous permissive or ambiguous language for POEM and G-POEM has been revised to specify indications considered medically necessary (Achalasia, diffuse esophageal spasm) and those considered investigational/not medically necessary (G-POEM, other POEM indications); LINX and other endoluminal GERD therapies are explicitly listed as unproven/not medically necessary or investigational when not FDA-approved.

Benefit coverage is determined by the member-specific benefit plan document and applicable law. Medical records documentation may be required to verify that clinical criteria are met but does not guarantee coverage; prior authorization and review of submitted documentation may be required to confirm medical necessity.

Medical records may be requested to verify diagnosis, objective testing (e.g., esophageal manometry, gastric emptying scintigraphy), previous therapies, and treatment response.
Operative notes, procedure reports, and documentation of failed conservative/medical management should be provided when applicable.
Documentation does not guarantee coverage; benefit determination is made after review of submitted records and applicable plan terms.

Denial Risk

Denial risk for procedures lacking high-quality evidence

Denial risk for procedures lacking high-quality evidence. Procedures or indications considered investigational, unproven, or without sufficient evidence (e.g., G-POEM for gastroparesis, POEM for non-achalasia indications, certain endoscopic GERD therapies without FDA approval) are at high risk for denial.

G-POEM (gastric per oral endoscopic myotomy) for gastroparesis — investigational/not medically necessary per policy.
POEM for indications other than achalasia or diffuse esophageal spasm (e.g., Zenker's diverticulum) — investigational/not medically necessary.
Endoscopic therapies for GERD lacking FDA approval or sufficient evidence (e.g., GERDx™) — investigational/not medically necessary.

Documentation Required

Patient selection, documentation, counseling, and FDA labeling guidance

Patient selection and documentation expectations for advanced endoscopic myotomy procedures. Careful selection, objective testing, and documentation of prior therapies are required to support medical necessity reviews.

Patient selection and documentation for POEM/G-POEM/Z-POEM: provide indication, prior treatments, objective testing results, and rationale for procedure choice.
Assess prior therapy and objective testing: include results of esophageal manometry for achalasia/distal esophageal spasm and gastric emptying scintigraphy for gastroparesis when applicable.
Need for careful selection and counseling: document discussion of risks, benefits, alternatives, and expectant outcomes, including device labeling or lack thereof.
Use FDA labeling and contraindications as informational guidance where applicable; lack of FDA approval for an indication may influence coverage.
Procedure selection should follow current clinical guidelines and be documented in the record.
Member-specific benefit verification required: verify prior authorization requirements, coverage criteria, and any plan exclusions before scheduling.

G-POEM: Observational meta-analyses report clinical success approximately 70% at one year in pooled series; a small sham-controlled RCT showed benefit at 6 months but with serious adverse events; overall evidence quality judged low to very low with need for larger RCTs and longer follow-up.

Stretta (radiofrequency): RCTs and systematic reviews show mixed and low-quality evidence; some trials report no significant benefit versus sham while others report symptom and quality-of-life improvements; long-term comparative effectiveness versus fundoplication remains uncertain.

Endoscopic plication/suturing (EFTP, EndoCinch, EsophyX/MUSE): Some RCTs and series show symptom and PPI-use improvements in the short term (eg, EFTP RCT with ≥50% GERD-HRQL improvement), but durability beyond 12 months is inconsistent and objective acid exposure often not persistently improved; higher-quality long-term randomized data are needed.

Clinical guidance and technology assessments provide conditional support for some procedures but highlight uncertainty and the need for higher-quality long-term trials. For example, ACG/AGA guidance recognizes POEM as effective for type I/II achalasia and preferred for type III, and AGA/ACG offer conditional recommendations regarding GES and pyloromyotomy in refractory gastroparesis. Hayes HTAs and ECRI assessments characterize evidence for GES, G-POEM, and Stretta as low or very-low quality and call for larger randomized controlled trials with longer follow-up to clarify long-term efficacy, safety, and patient selection. Overall, guideline recommendations and HTA findings support selective use of certain proven procedures while noting important areas of uncertainty and the need for additional long-term RCTs.

Key evidence metrics

POEM pooled clinical success (all SEDs)WPR 87% (Khan et al. 2017)

POEM adverse events (WPR)Adverse events 11–16% across SEDs (Khan et al. 2017)

G-POEM clinical success ~1 yearApproximately 70% clinical success at 1 year (Mandarino et al. 2024)

G-POEM alternate pooled resultUsing a uniform 1-point GCSI reduction criterion, pooled success 92.8% at 1 year (Stojilkovic 2023)

G-POEM RCT (sham-controlled)Martinek 2022: G-POEM 15/21 vs sham 4/20 success at 6 months; 3 SAEs related to G-POEM

Enterra (GES) FDA statusEnterra Therapy System approved under HDE (March 31, 2000) for chronic intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis

02/01/2026removed

Language stating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing achalasia was removed.

02/01/2026added

Applicable CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to the policy.

02/01/2026revised

Supporting Information sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect most current information.

02/01/2026revisedLatest

Definitions section revised; definition of 'Gastroparesis' was updated.